In a phase 1 study, ELI-002 2P induced significant T-cell and biomarker responses in patients with immunotherapy-recalcitrant KRAS-mutant pancreatic and colorectal cancers with minimal residual disease (MRD) [10]. This evidence concerns the gene KRAS and colorectal cancer.